Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 951–1,000 of 1,441 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT01442714	Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk…	Phase 2	terminated	Sep 28, 2011	Stanford University	Lack of efficacy - Inability to meet the primary response endpoint	Efficacy / futility
NCT02193100	Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial…	—	withdrawn	Jul 17, 2014	University of Louisville	not stated	Not stated
NCT00295880	Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating…	Phase 1 / Phase 2	terminated	Feb 24, 2006	Masonic Cancer Center, University of Minnesota	Time to engraftment would not be improved compared to historical controls.	Other (stated, no rule matched)
NCT00354172	Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood…	Phase 2	terminated	Jul 20, 2006	Masonic Cancer Center, University of Minnesota	Competing study was started.	Other (stated, no rule matched)
NCT00392782	Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease	Phase 2	terminated	Oct 26, 2006	Masonic Cancer Center, University of Minnesota	not stated	Not stated
NCT00602446	Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell…	Phase 2	terminated	Jan 28, 2008	Masonic Cancer Center, University of Minnesota	Due to slow accrual of patients	Enrollment / accrual
NCT00609739	Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia…	Phase 1 / Phase 2	terminated	Feb 7, 2008	Masonic Cancer Center, University of Minnesota	Low accrual	Enrollment / accrual
NCT00625729	Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating…	Phase 1 / Phase 2	terminated	Feb 28, 2008	Masonic Cancer Center, University of Minnesota	No patients exhibited natural killer cell expansion (primary endpoint).	Other (stated, no rule matched)
NCT00818649	Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or…	Phase 2	terminated	Jan 8, 2009	Masonic Cancer Center, University of Minnesota	Met protocol stop rule \[i.e., extreme toxicity\]	Safety / toxicity
NCT00871689	Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin,…	Phase 2	terminated	Mar 30, 2009	Masonic Cancer Center, University of Minnesota	Due to graft failure.	Other (stated, no rule matched)
NCT00882206	Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute…	Phase 2	terminated	Apr 16, 2009	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT00963872	Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and…	Phase 1 / Phase 2	terminated	Aug 24, 2009	Masonic Cancer Center, University of Minnesota	Lack of efficacy after interim analysis	Efficacy / futility
NCT01106950	Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous…	Phase 2	terminated	Apr 20, 2010	Masonic Cancer Center, University of Minnesota	study drug (Ontak) no longer available	Other (stated, no rule matched)
NCT01312818	Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic…	Phase 2	terminated	Mar 11, 2011	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT01464359	T-Cell Depleted Double UCB for Refractory AML	Phase 2	terminated	Nov 3, 2011	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT03100877	Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating…	Phase 1 / Phase 2	withdrawn	Apr 4, 2017	City of Hope Medical Center	Feasibility Issues	Other (stated, no rule matched)
NCT02049801	MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or…	Phase 1	terminated	Jan 30, 2014	Bruno C. Medeiros	logistics	Other (stated, no rule matched)
NCT00176839	Stem Cell Transplantation for Hematological Malignancies	Phase 2 / Phase 3	terminated	Sep 15, 2005	Masonic Cancer Center, University of Minnesota	Replaced by a different study	Other (stated, no rule matched)
NCT01207076	AHN-12 Biodistribution in Advanced Leukemia	Phase 1	terminated	Sep 22, 2010	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT01343368	Preservation of Ovarian Function After Hematopoietic Cell Transplant	Phase 2	terminated	Apr 28, 2011	Masonic Cancer Center, University of Minnesota	not stated	Not stated
NCT02765997	StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies	Phase 2	withdrawn	May 9, 2016	Masonic Cancer Center, University of Minnesota	IRB Disapproval	Other (stated, no rule matched)
NCT00376519	Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood…	Phase 1	terminated	Sep 15, 2006	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT01163201	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in…	Phase 1 / Phase 2	withdrawn	Jul 15, 2010	Masonic Cancer Center, University of Minnesota	Replaced by a new study	Other (stated, no rule matched)
NCT01639456	CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell…	Phase 2	withdrawn	Jul 12, 2012	Masonic Cancer Center, University of Minnesota	study was abandoned and a new study was written to replace this one	Other (stated, no rule matched)
NCT01677949	Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute…	Phase 2	withdrawn	Sep 3, 2012	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT00005984	Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated…	Phase 2	terminated	Jan 27, 2003	Masonic Cancer Center, University of Minnesota	Study terminated as principal investigator \[PI\] left the university.	Investigator
NCT00005986	Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With…	Phase 2	terminated	Feb 12, 2004	Masonic Cancer Center, University of Minnesota	Principal investigator left the university.	Investigator
NCT00290628	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	N/A	terminated	Feb 13, 2006	Masonic Cancer Center, University of Minnesota	Replaced with another study	Other (stated, no rule matched)
NCT00369291	CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant	Phase 1	terminated	Aug 29, 2006	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT00618696	Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced…	Phase 1	terminated	Feb 20, 2008	Masonic Cancer Center, University of Minnesota	Replaced with another study	Other (stated, no rule matched)
NCT00643240	Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory…	Phase 1	terminated	Mar 26, 2008	Masonic Cancer Center, University of Minnesota	Due to slow accrual	Enrollment / accrual
NCT00725062	Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor…	Phase 1	terminated	Jul 30, 2008	Masonic Cancer Center, University of Minnesota	Slow accrual.	Enrollment / accrual
NCT03108911	Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia…	Phase 2	terminated	Apr 11, 2017	Rutgers, The State University of New Jersey	limited resources	Other (stated, no rule matched)
NCT02433483	Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger…	Phase 2	terminated	May 5, 2015	St. Jude Children's Research Hospital	The study was closed due to poor accrual and because of competing protocols.	Enrollment / accrual
NCT00101140	Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission	Phase 2	withdrawn	Jan 10, 2005	Eastern Cooperative Oncology Group	not stated	Not stated
NCT00281879	Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With…	Phase 2	terminated	Jan 25, 2006	OHSU Knight Cancer Institute	not stated	Not stated
NCT00416884	Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML	Phase 2	terminated	Dec 28, 2006	OHSU Knight Cancer Institute	Low enrollment	Enrollment / accrual
NCT02662296	Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic…	Phase 2	withdrawn	Jan 25, 2016	Fred Hutchinson Cancer Center	Low enrollment	Enrollment / accrual
NCT02485353	Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older…	N/A	terminated	Jun 30, 2015	Hamid Sayar	Safety concerns	Safety / toxicity
NCT02677948	Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic…	Phase 1 / Phase 2	withdrawn	Feb 9, 2016	University of Michigan Rogel Cancer Center	FDA has placed all trials involving Pacritinib on Full Clinical Hold	Other (stated, no rule matched)
NCT03138395	iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML(iCare3)	—	withdrawn	May 3, 2017	University of Florida	Study design modified to collect specimens from a bank requiring a separate IRB-approved protocol.	Other (stated, no rule matched)
NCT00957580	Trial of Pimasertib in Hematological Malignancies	Phase 2	terminated	Aug 12, 2009	EMD Serono	The trial has been terminated due to an estimated low probability of clinical benefit based on…	Safety / toxicity
NCT02255162	Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML	Phase 1	terminated	Oct 2, 2014	Massachusetts General Hospital	Slow Accrual	Enrollment / accrual
NCT01085656	A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS	Phase 1	terminated	Mar 12, 2010	University of Florida	not stated	Not stated
NCT01383447	Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory…	Phase 1 / Phase 2	terminated	Jun 28, 2011	National Cancer Institute (NCI)	This study was halted prematurely by the NCI for low accrual.	Enrollment / accrual
NCT01034592	Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent…	Phase 1	terminated	Dec 17, 2009	Jason Robert Gotlib	Poor accrual related to rarity of Diamond-Blackfan anemia (DBA)	Enrollment / accrual
NCT01551628	A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or…	Phase 1	terminated	Mar 13, 2012	Bio-Cancer Treatment International Limited	slow patient recruitment	Enrollment / accrual
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed…	Phase 2	terminated	Aug 18, 2011	Fred Hutchinson Cancer Center	Low accrual	Enrollment / accrual
NCT03141398	Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in…(CGMs)	—	withdrawn	May 5, 2017	Hamad Medical Corporation	Due to issues with study design	Other (stated, no rule matched)
NCT00587457	A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic…	Phase 1	terminated	Jan 7, 2008	MedImmune LLC	The study is terminated early due to unavailability of investigational product.	Other (stated, no rule matched)

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 24 days agoSource updated Jan 3, 2018source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules